The gains in Cohance Lifesciences share price come after the company announced the appointment of former Cipla CEO Umang Vohra as Executive Chairman and Group CEO, effective from next month.
Vohra will succeed Vivek Sharma, who is stepping down as Executive Chairman for personal reasons. Sharma will remain associated with Cohance as an advisor for the next nine months to ensure a smooth transition.
The company said the appointment reflects a deliberate and strategic decision by the Board to bring in a leader whose profile is well aligned with the company’s transformation journey and its next phase of growth.
“I believe deeply in the long-term value creation potential of this platform. Cohance’s technology offerings, depth of its R&D talent, and the quality of the leadership team already in place provide a strong foundation. I am looking forward to this entrepreneurial stint and will work closely with the current management leaders to create value for customers, employees and shareholders alike,” Vohra said in a statement.
With a career spanning more than three decades, Vohra has led large and complex global businesses through phases of strategic transformation while maintaining a strong focus on customers, quality and operational excellence. Most recently, as CEO and Managing Director of Cipla Limited, he led the company’s transformation over the past decade into a diversified global pharmaceutical enterprise.
The company said that after working in and transforming two large and respected pharmaceutical companies in India, Vohra brings an owner mindset and extensive business experience to the Cohance platform.Cohance Lifesciences has built a differentiated presence in the global CDMO market through expertise in proprietary chemistry, complex multi-step synthesis and advanced process R&D. Its capabilities cover complex APIs, ADCs and oligonucleotides, complex intermediates, performance materials and speciality ingredients.
Also read: Adani Total Gas shares surge 8% to seven-month high after Q4 results, dividend announcement
With integrated R&D centres, more than 400 R&D scientists, and established partnerships with global pharmaceutical innovators, the company said its platform remains strongly anchored in science.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)